|
Malignant neoplasm of breast
|
0.330 |
Biomarker
|
disease |
BEFREE |
Vigilin, a nucleocytoplasmic shuttling protein, post-transcriptionally suppresses proto-oncogene c-fms expression (encoding CSF-1R) in breast cancer by binding to a 69 nt cis-acting 3-UTR element in CSF-1R mRNA.
|
30292064 |
2019 |
|
Malignant neoplasm of breast
|
0.330 |
AlteredExpression
|
disease |
BEFREE |
Multidimensional analysis of microarray datasets demonstrated up-regulation of genes encoding HBP enzymes in clinical breast cancers and revealed that co-expression of hyaluronan synthase 2 (HAS2) and glutamine:fructose-6-phosphate amidotransferase (GFAT), a rate-limiting enzyme of the HBP, was strongly correlated with a poor prognosis in advanced cancer patients.
|
31645543 |
2019 |
|
Malignant neoplasm of breast
|
0.330 |
Biomarker
|
disease |
BEFREE |
In summary, we identified a competition for binding the 69-nt sequence, through which vigilin and HuR exert opposing effects on c-fms expression, suggesting a role for vigilin in suppression of breast cancer progression.
|
20974809 |
2011 |
|
Malignant neoplasm of breast
|
0.330 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
|
Autistic Disorder
|
0.310 |
GeneticVariation
|
disease |
BEFREE |
FARP2, HDLBP and PASK are downregulated in a patient with autism and 2q37.3 deletion syndrome.
|
19365831 |
2009 |
|
Autistic Disorder
|
0.310 |
Biomarker
|
disease |
CTD_human |
FARP2, HDLBP and PASK are downregulated in a patient with autism and 2q37.3 deletion syndrome.
|
19365831 |
2009 |
|
Chromosome 2q37 deletion syndrome
|
0.300 |
Biomarker
|
disease |
CTD_human |
FARP2, HDLBP and PASK are downregulated in a patient with autism and 2q37.3 deletion syndrome.
|
19365831 |
2009 |
|
Body Height
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Eosinophil count procedure
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Tonometry
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genome-wide association analyses identify new loci influencing intraocular pressure.
|
29617998 |
2018 |
|
Smoking
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genome-wide meta-analysis of 241,258 adults accounting for smoking behaviour identifies novel loci for obesity traits.
|
28443625 |
2017 |
|
Fibrinogen assay
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Comparison of HapMap and 1000 Genomes Reference Panels in a Large-Scale Genome-Wide Association Study.
|
28107422 |
2017 |
|
Smoking Behaviors
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genome-wide meta-analysis of 241,258 adults accounting for smoking behaviour identifies novel loci for obesity traits.
|
28443625 |
2017 |
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Meta-analysis of genome-wide association studies discovers multiple loci for chronic lymphocytic leukemia.
|
26956414 |
2016 |
|
Fibrinogen assay
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
A meta-analysis of 120 246 individuals identifies 18 new loci for fibrinogen concentration.
|
26561523 |
2016 |
|
Small Lymphocytic Lymphoma
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Meta-analysis of genome-wide association studies discovers multiple loci for chronic lymphocytic leukemia.
|
26956414 |
2016 |
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation
|
disease |
GWASDB |
Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia.
|
23770605 |
2013 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.050 |
Biomarker
|
disease |
BEFREE |
Home blood pressure is associated with cognitive impairment among elderly patients with type 2 diabetes: KAMOGAWA-HBP study.
|
31081363 |
2019 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.050 |
Biomarker
|
disease |
BEFREE |
Isolated high home systolic blood pressure in patients with type 2 diabetes is a prognostic factor for the development of diabetic nephropathy: KAMOGAWA-HBP study.
|
31711859 |
2019 |
|
Diabetic Nephropathy
|
0.050 |
Biomarker
|
disease |
BEFREE |
Maximum morning home systolic blood pressure is an indicator of the development of diabetic nephropathy: The KAMOGAWA-HBP study.
|
30884176 |
2019 |
|
Diabetic Nephropathy
|
0.050 |
Biomarker
|
disease |
BEFREE |
Isolated high home systolic blood pressure in patients with type 2 diabetes is a prognostic factor for the development of diabetic nephropathy: KAMOGAWA-HBP study.
|
31711859 |
2019 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.050 |
Biomarker
|
disease |
BEFREE |
Impact of masked hypertension on diabetic nephropathy in patients with type II diabetes: a KAMOGAWA-HBP study.
|
29548933 |
2018 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.050 |
Biomarker
|
disease |
BEFREE |
Threshold value of home pulse pressure predicting arterial stiffness in patients with type 2 diabetes: KAMOGAWA-HBP study.
|
29447439 |
2018 |
|
Diabetic Nephropathy
|
0.050 |
Biomarker
|
disease |
BEFREE |
Impact of masked hypertension on diabetic nephropathy in patients with type II diabetes: a KAMOGAWA-HBP study.
|
29548933 |
2018 |
|
Diabetic Nephropathy
|
0.050 |
Biomarker
|
disease |
BEFREE |
Prognostic significance of home pulse pressure for progression of diabetic nephropathy: KAMOGAWA-HBP study.
|
29540826 |
2018 |